RCEL

AVITA Medical's stock (RCEL) has shown significant upward trends, increasing by 177.22% in the last six months and 100.92% over the past year, rising from $3.45 on January 1st, 2026, to $11.49 by September 23, 2026. Key events impacting the stock price include strong Q2 2026 earnings, which reported $21.7 million in GAAP total revenues (an 18% year-over-year increase) and led to a 17.66% stock gain. The company also raised its full-year 2026 revenue guidance to $86 million to $89 million and expects to achieve cash flow breakeven in Q4 2026. Positive results from the PermeaDerm-I clinical study in August 2026 demonstrated comparable clinical outcomes to cadaveric allograft with a 70% cost reduction, while interim Cohealyx I study data in April 2026 showed faster time to skin grafting readiness. The international rollout of RECELL GO, following CE Mark approval in September 2025 and launches in Australia, New Zealand, and the UK, has expanded the company's reach. Additionally, physician utilization of RECELL has increased due to the stabilization of physician reimbursement.